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EDITORIALS 
Transformation in Cutaneous T-Cell Lymphoma 
T he term "transformation" describes those cases of my-cosis fungo ides (MF) and Sezary syndrome (SS) in which the tumors or enlarged lymph nodes display histologic features that closely resemble or are indis-tinguishable from those seen in malignant lympho-
mas. Understanding the phenomenon of transformation is central 
to our understanding of the pathogenesis and, perhaps, eventually 
the etiology of these disorders. The concept and the application of 
the term transformation is best understood in the context of the 
historical development of MF. 
Alibert described MF in 1806. He called it pian fungo ides because 
he believed it was a form of yaws with large necrotic tumors, but he 
later changed the name to mycosis fungo ides because the tumors 
resembled mushrooms. In 1876, Bazin, one of Alibert's students, 
recognized and described the classic three stages of MF. In 1885, 
Vidal and Brocq introduced the term mycosis fungoides a tumeurs 
d'emblee to delineate disorders having mushroom-like tumors that 
appeared in the absence of the first two phases of the disease. In 1891 
Hallopeau applied the term mycosis fungoides to diseases in which 
exfoliative dermatitis was the prime feature. Subsequently, most 
cases of lymphoma with tumors were called mycosis fungoides and 
vice versa. 
In 1938, Sezary and Bouvrain described the leukemic variant of 
MF - the Sezary syndrome. From the 1930s to the 1950s questions 
began to be raised about the relationship of MF to the malignant 
lymphomas: was it a cutaneous manifestation of an established lym-
phoma or did it undergo transformation to other lymphomas [1- 3] 
such as the lymphocytic, or to histiocytic types or Hodgkin's dis-
ease? This confusion had stemmed from the inclusion of cases of 
malignant lymphoma in series dealing with MF; and from misinter-
preting the histologic alterations in the lymph nodes and viscera of 
MF as malignant lymphoma. From 1858, when the term lymphoma 
was first used by Virchow, until 1966, lymphomas were classified 
generally into four major groups: lymphosarcoma, reticulum cell 
sarcoma, giant follicular (nodular) lymphoma, and Hodgkin's dis-
ease [4]. In 1966, Rappaport proposed a classification of the non-
Hodgkin's lymphomas based upon their histologic growth patterns 
and cytologic features observed in affected lymph nodes [5]. Al-
though it was subsequently modified, it continued to prove useful 
for prognostic and descriptive purposes. At that time, the functional 
cell types in the immune system and in normal lymph nodes were 
largely unknown. Similarly, it was not known that lymphocytes 
could be transformed into larger cells with high proliferative activity 
in response to antigenic or mitogenic stimulation, and that similar 
transformations could be observed in neoplastic conditions. It was 
only in 1974 that a classification of non-Hodgkin's lymphomas 
based upon the newly emerging knowledge of the B- and T-cell 
systems was proposed by Lukes and Collins [6] . Lukes and Collins 
also emphasized the phenomenon of lymphocyte transformation in 
neoplastic disorders. Their proposed classification was a combina-
tion of morphology and putative function of the B- and T-cell 
systems as it was understood at that time. In 1985 and 1988, Saus-
ville and colleagues proposed an analogous system for histopatho-
logic classification of lymph node involvement in CTCL [7,8], 
which they believed would enhance the prognostic value of the 
currently used TNM staging system. Their system also was based 
upon the number and distribution of three types of abnormallym-
phocytes within the nodes: the small or large cell with cerebriform 
nuclei; the immunoblastic (transformed) lymphoid cell with 
slightly basophilic or clear cytoplasm and large nuclei with promi-
nent nucleoli; and large cells with multiple or multi-lobed nuclei 
closely resembling Sternberg-Reed cells. The old terms of reticu-
lum cell sarcoma and lymphoblastic lymphoma have been aban-
doned and replaced by the current nomenclature of large celllym-
phoma, small cell (cleaved or non-cleaved) lymphoma, and mixed 
small and large cell lymphoma [4,5]. 
In 1974, the concept that MF was an expression of an underlying 
malignant lymphoma was laid to rest by Rappaport and Thomas [9], 
and Long and Mihm [10] who showed that MF was a disease sui 
gerleris with extracutaneous histologic features similar to those 
pres~nt in the skin lesions. Although there was a preponderance of 
atypl~~1 lYI1~phOid cells in the viscera and nodes, the criteria for a 
defimtlve diagnoSIS of malignant lymphoma were lacking. These 
studies also indicated that the conversion of MF to a malignant 
lymphoma, if it actually occurred, was an uncommon event. At 
about the same time, the scientific foundations of MF and SS began 
to be established. In 1968, Lutzner and Jordan described the ultra-
structure of the Sezary cell [11]. The cell was shown to have abnor-
mal cytogenetics; to be a T lymphocyte that was sufficiently differ-
entiated to demonstrate normal helper T-cell function; and to be 
present in the peripheral blood, skin, and lymph nodes of MF and 
SS. Cytogenetic studies established chromosomal abnormalities in 
the skin, blood, and lymph nodes at all stages of MF and SS, even in 
the absence of leukemic cells and diagnostic histopathology in the 
nodes [12]. The chromosomal abnormalities were shown to be 
clonal in advanced stages of disease. With the advent of molecular 
biologic techniques, gene rearrangements of the p and y chains of 
the T-cell antigen receptor have been demonstrated, indicating and 
confirming the presence of malignant T-celI clones in advanced 
disease as suggested by the earlier cytogenetic studies. 
In the tumor phase of MF, the polymorphous band-like infiltrate 
is no longer confined to the upper dermis; the entire dermis and 
subcutaneous layer is affected. Epidermotropism virtually disap-
pears. The factors responsible for the shift from the epidermotropic 
to the non-epidermotropic histology that ushers in the aggressively 
malignant phase of the disease are unknown. The phenomenon of 
transformation in skin and lymph nodes is generally associated with 
aggressive clinic.al diseas.e. Although atypical and malignant-ap-
peanng lymphOid celIs mcrease in number and often produce a 
monomorphous mass, in most cases the atypical cells continue to be 
associated with mature lymphocytes, eosinophils, histiocytes, and 
plasma cells. Even when the histologic appearance of a tumor is 
truly monomorphous, one can sometimes find the characteristic 
polymorphous infiltrate in an adjacent field [13]. The plasma cell 
infiltration may be extensive [14]. In 1972, Epstein et at [15] had 
identified the basic factors defining prognosis and risk in MF and SS: 
extent and type of skin lesions, presence or absence of lymphade-
nopathy, and presence or absence of visceral involvement. They 
showed that the development of tumors or lymphadenopathy was 
associated with a survival rate of 50% at 2.5 years. 
Because of the chronicity of MF and the fact that the earlier work 
by Rappaport and Thomas had established that MF was not an 
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expression of a malignant lymphoma, a consensus developed among 
workers in this disease that the tumor stage and adenopathy repre-
sented the development of a predominant subclone or subclones 
from the original malignant T cells in the disease. This hypothesis 
has been greatly strengthened by the paper by Wood et af in this 
issue. They demonstrated by molecular biologic techniques in a 
single patient that the tumor cells from a plaque and from a tumor 
came from the same T-cell clone. In this case report, however, the 
patient was a man who had had MF from age 51 years, and had 
evolved from the plaque to the tumor stage at age 69 to 72 without 
yet having developed adenopathy. At age 75, he was still developing 
plaques and tumors. Transformation is usually accompanied by ade-
nopathy and a rapid downhill course. The case reported by Wood et 
af does not conform to this more usual syndrome. But their case did 
show that T cells can be transformed in the evolution of plaque to 
tumor-stage disease. Nevertheless, the probability is high that the 
same process is responsible for the adenopathy that often occurs 
with the tumor stage. However, to rigorously prove that this same 
phenomenon occurs with pathologic adenopathy, one will have to 
repeat these studies in the MF patient who develops adenopathy 
with the histology of large cell lymphoma. This would eliminate 
any possibility that an independent lymphoma has developed in 
such a patient. Interestingly, almost all the lymphoma cells in the 
case report ofW ood et al were described as immunoblastic. Only 1 % 
were described as anaplastic. Yet the tumor was strongly positive for 
CD30 (Ki-l), which is usually associated with anaplastic large cell 
lymphoma. 
Ki-l positive anaplastic lymphoma is a very aggressive neoplasm 
that is usually systemic in nature and devoid of cutaneous involve-
ment. There have been cases with skin lesions in which Ki-1 posi-
tive cells have been identified in the skin. In such cases, the disease 
has not behaved aggressively [16-18]. It is possible that some cases 
of so-called primary cutaneous Hodgkin's disease diagnosed in the 
past represented this syndrome or type A lymphomatoid papulosis. 
We have identified a man with disseminated clusters of erythema-
tous papules that showed the classic histology of MF, but also con-
tained many Ki-1-positive cells. Concomitantly, he developed 
unilaterally enlarged inguinal nodes with the histology of Ki-l 
positive anaplastic lymphoma. However, his disease pursued an in-
dolent course. He was treated with total body electron beam ther-
apy, which produced a complete clinical and histologic remission. 
The previously involved inguinal nodes could no longer be felt, nor 
could they be visualized on follow-up examination by CT scan. The 
relationship between Ki-1- positive lymphomas with skin involve-
ment and cutaneous T -cell lymphoma needs to be pursued. The case 
described by Wood et af displayed a slowly rrogressive course in the 
plaque/tumor stage. The Ki-1 positivity 0 the tumor may indicate 
that their patient's disease falls into the same category as described 
above for the Ki-1-positive anaplastic lymphomas with skin le-
Sions. 
Most instances of MF evolving into Hodgkin's disease and "retic-
ulum cell" sarcoma that were reported frequently prior to the defin-
itive studies of Rappaport and Thomas were probably examples of 
MF in which there was transformation of lymphocytes with or 
without Ki-1 positivity. Transformed T cells can even resemble 
Sternberg-Reed cells. Transformation had not been appreciated be-
fore the studies of Luke and Collins. Transformation does occur in 
MF, but more work needs to be done in delineating the clinical 
attributes associated with it. In addition, one needs to determine 
whether there are both slowly and rapidly progressive forms of 
disease associated with transformation, and, if so, how they differ 
from each other. We may have to alter our concept of MF from a 
three-stage disease to a four-stage disorder in which the develop-
ment of malignant T-cell clones proceeds slowly through the 
patch/plaque stage disease, picks up speed in the tumor stage, and 
accelerates in a fourth stage whose histology becomes indistin-
guishable from that of independent malignant lymphomas. It is 
very likely that the morphologic changes that T cells are able to 
undergo in response to either antigenic stimulation or neoplastic 
stimuli are not only limited but are identical. Therefore, we should 
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not assume that the histology of immunoblastic large cell lym-
phoma is limited to non-Hodgkin'S lymphomas. It has been amply 
demonstrated that the lymph nodes in MF can assume this picture in 
the presence of typical MF histology in the skin [7,8] . 
Irwin M. Braverman 
Yale University School of Medicine 
New Haven, Connecticut 
REFERENCES 
1. Symmers 0 : Mycosis fungoides as a clinical and pathologicnonexistent. A rch 
Dermatol Syph 25:1-5,1932 
2. Gates 0: Cutaneous tumors in leukemia and lymphoma. Arch Dermatol Syph 
37:1015-1030,1938 
3. Cawley EP, Curtis AC, Leach JEK: Is mycosis fungoides a reticuloendothelial 
neoplastic entity? Arch Dermatol Syph 64:255 - 272, 1951 
4. Jaffe ES: An overview of the classification of non-Hodgkin's lymphomas. In: Jaffe 
ES (cd.). Surgical Pathology oJthe Lymph Nodes alld Reiated OrgaflS. Major Problems 
ill Pathology, Vol. 16. WB Saunders, Philadelphia, 1985, p 135 
5. Rosenberg SA, Berard CW, Brown BW, et al: N ational Cancer Institute spon-
sored study of classification on non-Hodgkin's lymphomas: summary and de-
scription of a working formulation for clinical usage. Callcer 49:2112,1981 
6. Lukes RJ, Collins RD: New approaches to the classification of the lymphomata. 
Br J Catuer 31 (suppl II) , 1975 
7. Sausville EA, Eddy JL, Makuch R W , et al: Histopathologic staging at initial 
diagnosis of mycosis fungo ides and Sezary syndrome. Definition of three dis-
tinctive prognostic groups. Anll Intem Med 109:372-382,1988 
8. Sa us ville EA, Worsham GF, Matthews MJ, et al: Histologic assessment of lymph 
nodes in mycosis fungo ides/Sezary syndrome (cutaneous T-cell lymphoma): 
clinical correlations and prognostic import of a new classification system. Hum 
PatIJO/16:1098-1109,1985 
9. Rappaport H, Thomas LB: Mycosis fungoides: the pathology of extracutaneous 
involvement. Callter 34:1198-1229, 1974 
10. Long JC, Mihm MC: Mycosis fungoides with extr.cutaneous dissemination: a 
distinct clinicopathologic entity. Callcer 34:1745-1755,1974 
11. Lutzner MA,Jordan HW: The ultrastructure of an abnormal cell in Sezary Syn-
drome. Blood 31 :719-726,1968 
12. Lutzner M, Edelson R, Schein P, et al: Cutaneous T-cell lymphomas: the Sezary 
syndrome, mycosis fungoides, and related disorders. AIIII IlIlem Med 83:534 -
552, 1975 
13. Montgomery H: Dermatopathology. Harper & Row, New York, 1967, Fig 37-4, p. 
1207 
14. Allen AC: The Skin. A Clillicopathologic Treatise, 211d ed. Grune & Stratton, New 
York, p. 1120, 1967. 
15. Epstein EH Jr, Levin DL, Croft JD Jr, Lutzner MA: Mycosis fungoides. Survival , 
prognostic features, response to therapy, and autopsy findings. Medicine 15:61 -
72,1972 
16. Kadin M: The spectrum of Ki-l + cutaneous lymphomas. C,m Probl Dennatol 
19:132-143,1990 
17. Kaudewitz P, Burg G, Stein H: Ki-l (CD30) positive cutaneous anaplastic large 
cell lymphomas. Cu" probl Dermalo/19:150-156, 1990 
18. LindholmJS, Barron DR, Williams ME: Ki-l-positive cutaneous I.rge cel ilym-
phoma of T-cell type: Report of an indolent subtype. J Am Acad Dennatol 
20:342-348,1989 
A casual observer of retinoid research over the past five years 
could be forgiven for thinking that the role of retinoic acid, a deriv-
ative of vitamin A (retinol), in tissue development and maintenance 
is close to being understood. Yet, despite the tremendous advances 
in characterizing at least one mechanism of action of retinoic acid, 
that of its role in transcriptional regulation via the nuclear retinoic 
acid receptors (RARs) and retinoid X receptors (RXRs), we are still 
far from understanding how changes in intracellular concentrations 
of this molecule are regulated during development and how conse-
quential effects at the level of single genes or sets of genes determine 
cell phenotype. Since the identification of 9-cis retinoic acid as the 
ligand for RXRs and an additional ligand for RARs, experimental 
evidence increasingly favours RAR-RXR heterodimers as media-
tors of some biologic responses to retinoic acid. More than ever, we 
need to understand the mechanism and regulation of transfer of 
retinol into cells, the factors that regulate the synthesis of retinoic 
acid from retinol, and the mechanisms by which intracellular levels 
of the all-trans and 9-cis isomers of retinoic acid are regulated. 
Dermatology is one discipline that is leading the way in retinoid 
research, driven by the tremendous potential of retinoids for treat-
ing acne, deskeratotic diseases, photodamage, and skin cancer. In 
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recent years, John Voorhees' group at the University of Michigan 
has made major contributions to the cellular and molecular biology 
of retinoids in human skin. Another paper from his laberatery, by 
Christopher Griffiths and colleagues on. p. 325, highlights ~ome 
impertant issu.es cencermng the ~echam~m ?f the therapeutic ef-
fects of retinOlds and the properties ef retmOld analegues. 
Griffiths et af (1) have cempared the effects of all -trans retinoic 
acid and CD271, a retinoic acid analegue, on human skin morphel-
ogy and histology. Normal buttock skin treated with retineic acid, 
CD271, or apprepriate vehicle under ecclusien fer 4 d has been used 
as the experimental model. Their main conclusion is that CD271, 
when used at deses effective in the treatment ef acne, produces few 
of the morphelogic and histologic changes obtained with retinoic 
acid treatment, but, like retinoic acid, dees result in a significant 
increase in expressien ef mRNA coding for cellular retineic acid-
binding protein-II (CRABP-II). . . 
The CRABP-II gene pre meter has sequences representmg retl-
noic acid response elements (RAREs) to which RARs bind in a 
ligand-dependent manner, resulting in an inductien of CRABP-II 
transcriptien. The CRABP-II RARE elements, of wluch there are 
two, preferentially bind RAR-RXR heterodimers [2]. RARs can 
bind all-trans retineic acid and 9-cis retineic acid with apparently 
similar affinity, whereas RXRs bind only 9-cis retinoic acid [2]. 
Induction of CRABP-II expression by retineic acid in skin is there-
fere presumably RAR-mediated, but all-tral'/S retineic acid may ise-
merise in vivo to give 9-cis retinoic acid for binding to a heterodlmer 
RXR partner. The potential centributi~n of RXRs to. CRAB~-II 
induction in skin can, so. far, only be 1l1ferred from transfect10n 
experiments [2], and the e~te~t to. whic.h C~P-I! inductien i.n 
skin is dependent on the bl11dmg of 9-c1s retinOlC aCid to. RXRs IS 
also unknewn. In vitro, at least, CRABP-II induction by retineic 
acid is mere effective if all -traIlS and 9-cis retineic acid are used 
together [2]. CD271 is a structural analegue of all -trans retineic acid 
[3J and the fact thatit also induces CRABP-II expressien in human 
skin raises the questlen whether CD271 has any bmdmg affimty for 
RXRs, and, if not, whether RXRs participate in CRABP-II induc-
tion by CD271 and require endegenous 9-cis retineic acid. 
The fact that CD271 is therapeutically effective at deses capable 
of inducing CRABP-Il but which de net induce the merpheleg~c 
and histologic changes characteristic of high doses of all-trailS retl-
neic acid [1 J implies that the therapeutic preperties of CD271 may 
be mediated, like CRABP-II induction, by an RAR-dependent 
mechanism. If, as the authors hepe, the inductien ef CRABP-II 
turns out to be a sensitive marker for the potential therapeutic ef-
fects of retinoic acid, this suggests the exciting possibility that a 
combinatien ef CD271 with a stable analegue ef 9-cis retinoic acid 
might have censiderable therapeutic potential. Alternatively, be-
cause 9-cis retinoic acid binds to RARs with a similar affinity to 
all-trans retineic acid, stable analogues er 9-cis retineic acid ceuld be 
more potent than all-trailS retinoic acid analogues in the treatment 
ef seme skin diseases. However, ene thing is certain: we need to 
know much more about the mechanism of retinoic acid in counter-
acting disease and the role ef different classes of nuclear recepters 
such as RARs and RXRs. 
The affinity of CD271 for RARs is 10-80 times lower than 
all-trailS retinoic acid [4J and this means that when equal deses ef 
CD271 and all -trans retinoic acid are compared, the effective dese of 
CD271 may in fact be equivalent to. a much lewer dese ef all-trailS 
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retineic acid. This could explain why Griffiths et af [1] feund that 
CD271 had little effect on proliferatien, skin morphology, and 
histology; as the authers point eut, lew cencentratiens ef all-tratls 
retinoic acid also. lack these effects yet still induce expression of 
CRABP-II. Nevertheless, a cemparisen between lew cencentra-
tions of all-trans retineic acid and CD271 at the dese used in this 
study may net be that simple. 
One interpretatien ef the fact that all-trailS retineic acid induces 
skin hyperplasia and has morphologic and histelogic effects at high 
deses is that these effects require the presence ef retineic acid over a 
relatively leng peried. Given that retineic acid may be rapidly me-
tabelized, a biolegically effective level ef retineic acid may only be 
sustainable frem a single application by using a high initial dose. 
Hewever, if, as may be the case with CD271, biolegically effective 
levels ef a retineid analegue can be sustained witheut appreciable 
metabo lism yet without causing hyperplasia or ether morphologic 
changes, this weuld imply that these effects ef retineids on skin 
actually require high doses ef retinoid and may be mediated by 
mechanisms ether than through RARs and RXRs. To disseciate the 
texic or irritant effects ef retineids frem their therapeutic effects en 
cell differentiation has been a major aim of pharmaceutical compa-
nies fer a number of years. Two routes to. achieve this aim are to. 
modify retinoid structure to either remove the toxicity asseciated 
with high doses, or to make the melecule much more stable so that 
biologically effective deses can be maintained fer lenger. Because 
biologic potency seems to cerrelate well with affinity for RARs but 
net with affinity for CRABP [5], the use ef stable retineid analegues 
that can be used at sub-toxic deses may prove to be a more effective 
appreach. C learly, we need to. knew mere ab, 'ut the metabelism of 
retineids and retineid analegues. Molecular techniques as illustrated 
by Griffiths et af [1] can be used as sensitive assays of response to. 
retineid analegues and the starting point ef clinical studies to. deter-
mine the molecular mechanism respensible fer the therapeutic ef-
fects ef these drugs. 
Christepher P. F. Redfern 
Medical Melecular Biolegy Group 
Department of Medicine 
University ef Newcastle 
Newcastle upen Tyne, U.K. 
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